期刊文献+

《EAU男性性功能障碍指南(2013)》PDE5i解读 被引量:11

Interpretation of EAU Guidelines on Male Sexual Dysfunction(2013) and clinical applications of PDE5i
暂未订购
导出
摘要 欧洲泌尿外科学会(The European Association of Urology,EAU)2013年发表了新的《EAU男性性功能障碍指南(2013年版)》(以下简称《指南》)。在ED和PE的流行病学、诊断、治疗等方面做了论述。本文通过对《指南》中PDE5i解读,旨在帮助全科医生更加合理应用PDE5i。 The European Association of Urology (EAU) published new Guidelines on Male Sexual Dysfunction in 2013. In this guideline, EAU discussed erectile dysfunction and premature ejaculation from the perspective of epidemiology, diagnosis and treatment. This article aims to help general practitioners to apply PDESi more properly in clinics by interpreting the new EAU Guidelines.
出处 《中国性科学》 2013年第10期10-13,共4页 Chinese Journal of Human Sexuality
关键词 欧洲泌尿外科学会 PDE5i 男性勃起功能障碍 EAU PDE.Si Erectile dysfunction
  • 相关文献

参考文献21

  • 1Lue TF.Erectile dysfunction.N Engl J Med,2000,342 (24):1802-1813.
  • 2Moncada I,Jara J,Subir D,et al.Efficacy of sildenafil citrate at 12 hours after dosing:re-exploring the therapeutic window.Eur Urol,2004,46(3):357-361.
  • 3Goldstein I,Lue TF,Padma-Nathan H,et al.Sildenafil Study Group.Oral sildenafil in the treatment of erectile dysfunction.J Med,1998,338 (20):1397-1404.
  • 4Stuckey BG,Jadzinsky MN,Murphy LJ,et al.Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes:results of a randomized controlled trial.Diabetes Care,2003,26(2):279-284.
  • 5Porst H,Padma-Nathan H,Giuliano F,et al.Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing:a randomized controlled trial.Urology,2003,62(1):121-125.
  • 6Brock GB,McMahon CG,Chen KK,et al.Efficacy and safety of tadalafil for the treatment of erectile dysfunction:results of integrated analyses.J Urol,2002,168(4 Pt 1):1332-1336.
  • 7Sáenz de Tejada I,Anglin G,Knight JR,et al.Effects of tadalafil on erectile dysfunction in men with diabetes.Diabetes Care,2002,25 (12):2159-2164.
  • 8Fonseca V,Seftel A,Denne J,et al.Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment:analysis of data from tadalafil clinical trials.Diabetologia,2004,47 (11):1914-1923.
  • 9Porst H,Rosen R,Padma-Nathan H,et al.The efficacy and tolerability of vardenafil,a new,oral,selective phosphodiesterase type 5 inhibitor,in patients with erectile dysfunction:the first at-home clinical trial.Int J Impot Res,2001,13(4):192-199.
  • 10Goldstein I,Young JM,Fischer J,et al; Vardenafil Diabetes Study Group.Vardenafil,a new phosphodiesterase type 5 inhibitor,in the treatment of erectile dysfunction in men with diabetes:a multicentre double-blind placebo-con-trolled fixed-dose study.Diabetes Care,2003,26 (3):777-783.

同被引文献113

引证文献11

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部